Herpes zoster vaccine (CanSino)

在漫长的历史长河中，人类面对传染病，往往都只能节节败退，直到疫苗的诞生。疫苗是人类控制传染病的主要手段，被视为20世纪最伟大的公共卫生成就之一。疫苗的发明起源于18世纪一次偶然的牛痘接种。1796年英国医生Edward Jenner给一个小男孩注射了牛痘疱液，使其成功获得了天花免疫力，这就是人类的第一支疫苗。随后，疫苗学逐步发展起来。疫苗的工作原理是通过模拟人体自然感染病原体过程使人体主动产生抗体，进而在病原体再次感染时能够快速产生免疫应答。随着生物技术的快速发展，疫苗技术不断升级迭代，从传统的减毒活疫苗、灭活疫苗、亚单位疫苗等，逐渐发展为基因工程疫苗、重组载体疫苗、核酸疫苗等新型疫苗，同时在免疫原性和安全性方面取得了显著的提升和突破。2023年，我国疫苗行业迎来新一轮发展。从批签发情况看，2023年疫苗整体批签发次数为4379批次，同比下降6.9%。这主要是受部分产品渠道库存较多，对企业生产和发货端造成较大压力，以及部分企业停产的影响。其中，HPV疫苗、带状疱疹疫苗等重磅二类苗需求旺盛，持续放量。在疫苗产品管线布局方面，重磅产品管线领域有带状疱疹疫苗、肺炎疫苗、HPV疫苗、流感疫苗、狂犬病疫苗等；值得关注的新疾病领域疫苗有RSV疫苗、肿瘤mRNA疫苗等。国内部分疫苗的在研产品管线如下。值新春佳节之际，小编精选了关于疫苗在研发、生产、临床及应用等方面的15本书籍和大家一起学习交流，有兴趣的老师可以扫码登记，符合要求方可加入我们学习行列。快快加入我们喔，一起过一个充实而又愉快的春节！01 Vaccines for Neglected Pathogens: Strategies, Achievements and Challenges: Focus on Leprosy, Leishmaniasis, Melioidosis and TuberculosisThis book reviews successes and (remaining) challenges in vaccine development for the selected Neglected Tropical Diseases (NTD) of Leprosy, Leishmaniasis, Meliodoisis and Tuberculosis, which are a continuous burden for millions of people in affected areas worldwide. Written by frontline researchers, the volume deep-dives into different vaccine strategies, provides biotechnological background information and also tackles animal models in NTD therapeutics research. By bringing together state-of-the-art expert knowledge, the book contributes to the aim of ultimately ending the epidemics of neglected tropical diseases, complying with UN Sustainable Development Goal 3, Health and Well-Being. The volume highlights the activities of the research network VALIDATE (VAccine deveLopment for complex Intracellular neglecteD pAThogEns), funded by the Medical Research Council in the UK. The four NTDs discussed in the book were selected as these are in the focus of VALIDATE’s research. The book targets scientists and clinicians working on NTDs, as well as all readers with a background in biomedicine and interest in vaccine development. This is an open access book.02 Spray Drying of Vaccines: From Laboratory Research to Industrial ApplicationsThis book addresses the stabilization of vaccine powders by spray drying and provides an overview of the current state of the art on a laboratory and industrial scale. The book aims to familiarize readers with the advances in vaccine spray drying technology to understand its application potential better. In particular, the book addresses the design of aseptic spray dryers, parameters affecting the spray drying process, sterile powder processing, cleaning procedures, and powder filling. In addition, different drying technologies for the production of dry powder vaccines are compared to discuss the unique capabilities of spray drying as a particle technology for vaccines. Special attention is given to research studies on spray-dried vaccines published over the past 30 years, with key findings from laboratory research to clinical trials. Potential applications of spray-dried vaccines and routes of administration are presented in detail. Finally, an outlook is given on how close the aseptic spray-drying of vaccines is to the market and the challenges that need to be overcome to be commercially successful. The book's target audience is academics, researchers, vaccine developers, industry experts, students, and possibly funders, including government agencies, who are active in the field. In addition, the book is a reference source for those involved in the vaccine formulation and biopharmaceutical processing industry.03 Computational Vaccine DesignThis volume explores computational vaccine design and the technologies that support it. Chapters have been divided into four parts detailing immunonics and system immunology, databases, prediction of antigenicity and immunogenicity, and computational vaccinology. Written in the format of the highly successful Methods in Molecular Biology series, each chapter includes an introduction to the topic, lists necessary materials and reagents, includes tips on troubleshooting and known pitfalls, and step-by-step, readily reproducible protocols. Authoritative and cutting-edge, Computational Vaccine Design: Methods and Protocols aims to reflect on the rigorous and imaginative use of computational technologies to help catalyze future efforts and to improve global public health through the development of a broad range of novel vaccines.04 A History of Vaccines and Their OpponentsA History of Vaccines and Their Opponents describes the history of this opposition as well as its changing rationale over the years and in different societies. The Coronavirus pandemic that began in 2019 brought to the forefront the presence of a significant minority of individuals who strongly oppose vaccinations. However, this opposition is by no means recent. Ever since the very first attempts to immunize individuals, opposition has been intense in some societies. The reasons for this opposition range from religious, to political and medical. This discussion may ultimately provide some suggestions for reducing hesitancy in the future. Although vaccines have eliminated smallpox and largely eliminated polio and measles, opposition to vaccination persists and, in some countries, has grown stronger.05 The Marathon of the Messenger: A History of Messenger RNA VaccinesThe Covid-19 pandemic changed the world. Indeed a real race took place worldwide between SARS-CoV-2 on the one hand and researchers on the other – especially those specializing in messenger RNA vaccines. Four years after its emergence, the pandemic is not over, but some decisive battles have been won, thanks to the great success of mRNA vaccines. The Marathon of The Messenger presents the history of these mRNA vaccines, combining a scientific background with historical and economic perspectives. It appears that an important page in the history of these new vaccines was written in Europe, thanks to the crucial work of German and French scientists; this effort began in 1993 and continues to this day. In the face of a prevailing single-mindedness, these researchers pushed through a new therapeutic concept and defined the biotechnological keys that would open the way to the production of therapeutic messenger RNA in the fight against cancer and viral infections. Written for a broad audience and accompanied by humorous cartoons, this book will appeal to anyone looking for scientific and historical answers about mRNA vaccines. Readers will discover not only the technical and scientific knowledge of how these vaccines work, but also the economic levers that were necessary to create this technology. This book has been written in collaboration with Dr. Steve Pascolo, former director of CureVac, and the RNA messenger expert Professor Chantal Pichon. It also features a preface by Dr. Pierre Meulien, former director of the European Union public-private partnership Innovative Medicines Initiative (IMI).06 Access To Medicines And Vaccines: Implementing Flexibilities Under Intellectual Property LawThis book is the outcome of a Global Forum on Innovation, Intellectual Property and Access to Medicines held in December 2019 at the Max Plank Instititute in Munich, organised by the South Centre and the Max Plank Institute. The academics and experts from international organisations participating have contributed chapters to this book. The book is for policy makers (in Ministries of Health, Ministries of Trade, Ministries of Foreign Affairs, patent offices), but also relevant for academics (law, trade, public health), on the flexibilities available in the Agreement on Trade Related Aspects of Intellectual Property Rights (TRIPS) of the World Trade Organization to promote access to medicines.This volume provides a practical guide providing step-by-step methods and protocols on vaccine development and production. Divided into three volumes,Volume 3: Resources for Vaccine Development guides readers through chapters on vaccine adjuvants, vaccine vectors, production, vaccine delivery systems, vaccine bioinformatics, vaccine regulation, and intellectual property. Written in the format of the highly successful Methods in Molecular Biology series, each chapter includes an introduction to the topic, lists necessary materials and reagents, includes tips on troubleshooting and known pitfalls, and step-by-step, readily reproducible protocols.Authoritative and practical,Vaccine Design: Methods and Protocols, Second Edition, Volume 3: Resources for Vaccine Development aims to be a useful practical guide to researchers to help further their study in this field.08 Vaccine Design: Methods and Protocols, Volume 1. Vaccines for Human DiseasesThis volume provides a practical guide providing step-by-step protocol to design and develop vaccines for human diseases. Divided into three volumes,Volume 1: Vaccines for Human Diseases guides readers through an introductory section on future challenges for vaccinologists and the immunological mechanism of vaccines. Chapters focus on design of human vaccines for viral, bacterial, fungal, and parasitic diseases as well as tumor vaccines. Written in the format of the highly successful Methods in Molecular Biology series, each chapter includes an introduction to the topic, lists necessary materials and reagents, includes tips on troubleshooting and known pitfalls, and step-by-step, readily reproducible protocols.Authoritative and practical, Vaccine Design: Methods and Protocols, Second Edition, Volume 1: Vaccines for Human Diseases aims to be a useful practical guide to researchers to help further their study in this field.09 Vaccine Technologies for Veterinary Viral Diseases: Methods and ProtocolsThis detailed volume explores the most popular antigen production and delivery strategies that have been tested in veterinary species. Viral vectors as well as genetic and protein subunit vaccines or large scale protein production systems are considered as well as an updated view of most options available for vaccine development, including the data obtained through experimental trials which contributes to the exploration and understanding of the immune mechanisms and immune correlates relevant in protection among different animal species. Written for the highly successfulMethods in Molecular Biology series, chapters include brief introductions to their respective topics, lists of the necessary materials and reagents, step-by-step, readily reproducible laboratory protocols and tips on troubleshooting and avoiding known pitfalls.Authoritative and practical,Vaccine Technologies for Veterinary Viral Diseases: Methods and Protocols facilitates access to well-established protocols to those beginning in this interesting and laborious field as well as providing important basic knowledge when attempting a novel vaccine design or platform.10 mRNA VaccinesThe formulation and the technological advancements in RNA biology, chemistry, stability, and encapsulated delivery systems that have enabled the development of fully synthetic mRNA vaccines are discussed in this volume. The applications of the mRNA technology is covered, focusing on infectious diseases but also touching on other indications, such as immunotherapies and molecular therapies. Potent and long-lasting immune responses observed in animal models, encouraging data from early human clinical studies, together with the success of two mRNA-basedCOVID-19 vaccines support the use of mRNA-based vaccination as an attractive alternative to conventional vaccine approaches. Consequently, the development progress of the technology, particularly on production, capabilities, and clinical development is reviewed. Topics on safety, regulatory issues, and possible challenges to the mRNA vaccination approach round off this book. Thanks to their high potency, the prospect for generic, low-cost manufacturing processes, and entirely synthetic nature, the future for mRNA vaccines is highly promising. Importantly, mRNA vaccines have the potential to minimize the time between pathogen identification and vaccine release with a huge impact on public health.As the mRNA-based vaccination technology has been progressing rapidly, the book is intended to be an end-to-end review series, covering everything from basic RNA biology and preclinical studies to the manufacturing strategy, clinical development and regulatory approval. It provides established RNA researchers and developers with updates on the latest advancements in the field and allows for a quick but comprehensive overview of this transformative technology, its application, and future potential.11 Messenger RNA TherapeuticsProfessor Stefan Jurga conducts interdisciplinary scientific research in the field of nanoscience and nanotechnology, covering the physical, chemical, biological and medical sciences. He has authored over 270 publications in the interdisciplinary database Journal Citation Reports. He has served as Visiting Professor at, e.g., Cornell University, North Carolina State University, and the University of South Africa in Pretoria. He was a laureate of the Alexander von Humboldt Foundation and a scholarship holder at the Max Planck Institute for Polymer Research in Mainz (Germany). He has also worked at the University of Illinois at Urbana Champaign, at the Józef Stefan Institute in Ljubljana, and at many other international scientific institutions. He has served as Vice-Rector and Rector of the Adam Mickiewicz University Poznań (AMU) and also created the interdisciplinary NanoBioMedical Center at the AMU, which he has been the director of since 2010. From 2005 to 2007, he was appointed as the Under Secretary and Secretary of State for research and higher education at the Ministry of Education and Science and the Ministry of Science and Higher Education.Jan Barciszewski is Professor at Adam Mickiewicz University (AMU) in Poznań, Poland and at the Institute of Bioorganic Chemistry of the Polish Academy of Sciences, Poznań, Poland where he has worked since 1974. He studied organic chemistry at the AMU. During his Ph.D. studies, he worked on the structure and function of modified bases and nucleoside sequences of plant phenylalanine specific transfer ribonucleic acid (tRNA), including cytokinins. He was subsequently granted Doctor of Science degree for his work on the properties of plant tRNAs and aminoacyl-tRNA synthetases. In the 1990s, he began working on the diagnosis and therapy of brain tumors. He developed a new method for the transformation of plant mitochondria based on catalytic RNAs and is currently involved in studies on a new type of catalytic RNAs (enantiomeric ribozymes) for efficient RNA target cleavage in vivo, as well as the search for new anti-aging agents.12 Challenges and Opportunities of mRNA Vaccines Against SARS-CoV-2: A Multidisciplinary PerspectiveThis book offers an analytical look at the much debated risks and benefits of the newly developed COVID-19 mRNA-vaccines. As such, it is one of the firstbooks to give a comprehensive overview of mRNA vaccines against COVID-19 and the only one that addresses this topic from a broad multidisciplinary background. It brings together insights from various underlying disciplines on the challenges of developing and evaluating the most suitable vaccines for mass vaccination programs enrolled throughout the world - focusing on safety and efficacy.This book should not be missing on the shelf of any biomedical researcher, epidemiologist, public health professional or clinical researcher interested in SARS-CoV2 or virology and vaccine development in general. 13 mRNA Vaccine ToxicityReaders of our website [D4CE.org] will be aware that the mRNA vaccines that have been used against COVID-19 have caused injury and death on an unprecedented scale in the history of medicine.This book argues that these harms had to be expected from first principles of immunology. Furthermore, they are not limited to the COVID vaccines alone; instead, they are inherent in the mRNA technology as such. We must therefore expect that future mRNA vaccines against other viruses or bacteria will be similarly toxic. mRNA technology will never be safe to use for vaccination against any infectious agent.14 Textbook of Microbiology and ImmunologyThe fourth edition of “Textbook of Microbiology and Immunology” is an extensively revised edition , a healthy mixture of the old and the new contents. Many of the old traditional chapters have been retained with addition of new information along with the inclusion of new chapters more in line with the on-going changes in the syllabus and concepts in Medical Microbiology .While doing so, this book has blended the traditional organism-based learning and a syndrome based approach to infectious disease, together with the introduction of new and modified chapters incorporating the latest information in this field.The book provides an extensive coverage of fundamental topics in general and medical microbiology. The book also lays due emphasis on clinical microbiology with special focus on syndrome based approach to infectious diseases. It includes the basic concepts of microbiology as well as the recent updates and developments in the field of medical microbiology. All the topics have been incorporated in seven major sections: General microbiology, Immunology, Bacteriology, Virology, Mycology, and Applied and Clinical Microbiology.The dynamic nature of medical sciences with new guidelines and new diagnostic methods coming into the arena necessitates the incorporation of new information in each new edition of a book. This facet has been addressed with the inclusion of recent information on the various aspects of microbiology, infectious diseases and immunology, in the fourth edition of the Textbook of Microbiology and  Immunology ,which makes it one of the most authoritative and informative textbooks in medical microbiology.The book is an effort to inform and engage a wide spectrum of readers including medical students , both undergraduates and postgraduates, and residents, and faculty. It aims to be a must-have companion book for graduate and advanced undergraduate as well as postgraduate students of medical microbiology, general and allied microbiology, and of immunology.15.Vaccine Design Methods and Protocols, Volume 2. Vaccines for Veterinary DiseasesThis volume provides a practical guide providing step-by-step protocol to explore vaccines for farm and companion animals, as well as for fish and insects. Divided into three volumes, Volume 2: Vaccines for Veterinary Diseases guides readers through veterinary vaccines, vaccines for poultry, vaccines for farm animals, and vaccines for veterinary parasites. Written in the format of the highly successful Methods in Molecular Biology series, each chapter includes an introduction to the topic, lists necessary materials and reagents, includes tips on troubleshooting and known pitfalls, and step-by-step, readily reproducible protocols.Authoritative and practical, Vaccine Design: Methods and Protocols, Second Edition, Volume 2: Vaccines for Veterinary Diseases aims to be a useful practical guide to researchers to help further their study in this field. 识别微信二维码，添加生物制品圈小编，符合条件者即可加入生物制品微信群！请注明：姓名+研究方向！版权声明本公众号所有转载文章系出于传递更多信息之目的，且明确注明来源和作者，不希望被转载的媒体或个人可与我们联系(cbplib@163.com)，我们将立即进行删除处理。所有文章仅代表作者观点，不代表本站立场。

前言AIDD Pro 根据国内外各大网站以及人工智能药物设计主流新闻网站及公众号，从 AIDD会议、AIDD招聘，重大科研进展、行业动态、最新报告发布等角度，分析挖掘了每周人工智能辅助药物设计领域所发生的、对领域技术发展产生重大推动作用的事件，旨在帮助 AIDD领域研究人员和业内人士及时追踪最新科研动态、洞察前沿热点。如果您觉得符合以上要求的内容我们有遗漏或者更好建议，欢迎后台留言。科研进展2024年2月2日【靶向蛋白降解】ACS Chem. Biol. | 利用Cullin E3连接酶接头蛋白SKP1进行靶向蛋白降解2024年2月2日【SARS-CoV-2】ACS Appl. Bio Mater. | 羟基磷灰石-金修饰的丝网印刷碳电极用于选择性SARS-CoV-2抗体免疫传感器2024年2月1日【分子动力学模拟】J. Chem. Inf. Model. | 基于异构多核架构的大规模分子动力学模拟2024年2月1日【FDA药物】J. Chem. Inf. Model. | 从生物和化学数据洞察药物心脏毒性：FDA药物诱导心脏毒性等级的第一个公开分类器2024年1月31日【药物设计】J. Chem. Inf. Model. | 基于结构的溶质载体药物设计中的计算化学：最新进展和未来展望2024年1月31日【靶蛋白相互作用】J. Med. Chem. | 通过微管蛋白秋水仙碱位点优化的靶蛋白相互作用策略PM534具体信息，请滑动下方文字1.【靶向蛋白降解】靶向蛋白降解与蛋白水解靶向嵌合体(PROTACs)是通过靶向泛素化和蛋白酶体介导的降解来消除致病蛋白的一种强大的治疗方式。大多数PROTACs利用Cullin-RING E3泛素连接酶的底物受体，如小脑和VHL。Cullin-RING E3泛素连接酶复合物的核心组分、共享组分和基本组分是否可用于PROTAC应用尚不清楚。在这里，我们发现了一个半胱氨酸反应性共价招募者EN884，其靶向SKP1- cul1 - f -box中含有SCF复合物的SKP1适配蛋白。我们进一步表明，该招募物可用于PROTAC应用，以SKP1和蛋白酶体依赖的方式降解新底物蛋白，如BRD4和雄激素受体。我们的研究表明，Cullin-RING E3泛素连接酶复合物中的核心和必需的适配器蛋白可以用于靶向蛋白质降解应用，共价化学蛋白质组学策略可以针对这些靶标发现。链接网址：https://pubs-acs-org.libproxy1.nus.edu.sg/doi/10.1021/acschembio.3c00642DOI：https://doi-org.libproxy1.nus.edu.sg/10.1021/acschembio.3c006422.【SARS-CoV-2】严重急性呼吸综合征冠状病毒2型(SARS-CoV-2)或冠状病毒病2019 (COVID-19)仍在全球传播;因此，需要快速和准确的检测方法，以保持这种传染病的传播。电化学免疫传感器是快速检测SARS-CoV-2病毒的另一种方法。在此，我们报告了一种丝网印刷碳电极免疫传感器的开发，该传感器使用羟基磷灰石-金纳米复合材料(SPCE/HA-Au)直接喷涂固定受体结合域(RBD)钉，以增加电导率和表面电极面积。采用Box-Behnken法对HA-Au复合材料的合成进行了优化，并通过紫外-可见分光光度法、TEM-EDX和XRD分析对合成的HA-Au复合材料进行了表征。在[Fe(CN)6]4 - /3 -溶液氧化还原体系中，采用差分脉冲伏安法和电化学阻抗谱法研究了RBD Spike与免疫球蛋白G (IgG)抗体的特异性相互作用。IgG的检出限为0.0561 pg mL-1，免疫传感器的选择性和稳定性为103-122%，受储存条件的影响，稳定至第7周。此外，使用人血清的真实样品对免疫传感器进行了测试，其中使用化学发光微粒免疫测定(CMIA)方法证实了结果，并显示出令人满意的结果。因此，所研制的电化学免疫传感器能够快速准确地检测出SARS-CoV-2抗体。链接网址：https://pubs-acs-org.libproxy1.nus.edu.sg/doi/10.1021/acsabm.3c00953DOI：https://doi-org.libproxy1.nus.edu.sg/10.1021/acsabm.3c009533.【分子动力学模拟】随着分子动力学(MD)模拟应用的不断发展，对加速大规模模拟系统和处理大量模拟任务的需求正在稳步增加。提出了一种基于双威异构多核处理器的大规模MD仿真并行加速方法。该方法集任务调度、仿真计算和数据存储于一体，有效地解决了大规模仿真和大量仿真任务的相关问题。任务调度策略可以灵活处理各种规模的任务，实现多个任务并行执行。在仿真计算中，我们将GROMACS移植到Sunway架构中，并通过异构处理器加速了短程力的计算。我们的方法在执行单个模拟任务时实现了大约10倍的加速和90%的可扩展性。在处理大量仿真任务时，我们的方法实现了所有任务的并行执行，具有90%的可扩展性。利用我们的方法，我们在5小时内对3000多种不同的concontoxin结构分别进行了50 ns的模拟。此外，我们评估了200多种蛋白质配体复合物，模拟效率明显超过中小型GPU集群。链接网址：https://pubs-acs-org.libproxy1.nus.edu.sg/doi/10.1021/acs.jcim.3c01254DOI：https://doi-org.libproxy1.nus.edu.sg/10.1021/acs.jcim.3c012544.【FDA药物】药物引起的心脏毒性(DICT)是药物开发中的一个主要问题，占上市后停药的10-14%。在这项研究中，我们利用美国FDA最近发布的DICTrank数据集，探索了化学和生物数据预测心脏毒性的能力。我们发现，这些数据，包括蛋白质靶点，特别是与离子通道(如hERG)、物理化学性质(如电拓扑状态)和血浆峰浓度相关的数据，对DICT具有很强的预测能力。具有环加氧酶抑制等作用机制的化合物可以区分最受关注和不受关注的DICT。内质网应激的细胞绘画特征从无毒化合物中识别出最受关注的心脏毒性。基于物理化学性质的模型提供了相当高的预测准确性(AUCPR = 0.93)。随着未来组学数据的可用性，使用生物学数据有望提高可预测性和更深入的机制洞察，为更安全的药物开发铺平道路。本研究的所有模型均可在https://broad.io/DICTrank_Predictor上获得。链接网址：https://pubs-acs-org.libproxy1.nus.edu.sg/doi/10.1021/acs.jcim.3c01834DOI：https://doi-org.libproxy1.nus.edu.sg/10.1021/acs.jcim.3c018345.【药物设计】溶质载体转运蛋白(SLCs)是一类重要的跨膜蛋白，参与将各种溶质离子和小分子运输到细胞内。人体内大约有450种SLCs，其中超过四分之一的SLCs正在成为多种复杂疾病(如抑郁症、癌症和糖尿病)的有吸引力的治疗靶点。然而，只有44种独特的转运蛋白(约9.8%的SLC超家族)具有3D结构和特定的结合位点。为了设计针对不同SLCs的创新和有效的药物，需要克服许多障碍。然而，计算化学，包括基于物理的分子建模和基于机器学习和深度学习的人工智能(AI)，为经典的药物发现方法提供了一种替代和补充的方法。在这里，我们从三个主要方面全面概述了基于结构的SLCs药物设计计算技术的最新进展和存在的挑战:(i)表征蛋白质在运输功能过程中的多种构象，(ii)识别可药物位点，特别是底物和药物结合转运体上的隐变构位点，以及(iii)发现针对结合位点的各种小分子或合成蛋白质结合物。这项工作有望为深入理解SLC超家族的结构和功能提供指导，从而在包括人工智能在内的最先进的计算化学技术的帮助下，促进新型转运体调节剂的合理设计。链接网址：https://pubs-acs-org.libproxy1.nus.edu.sg/doi/10.1021/acs.jcim.3c01736DOI：https://doi-org.libproxy1.nus.edu.sg/10.1021/acs.jcim.3c017366.【靶蛋白相互作用】靶向微管是抗肿瘤化疗中最有效的广谱药物策略，目前的研究重点是减少其主要缺点:神经毒性和耐药。PM534是通过对天然分子PM742的结构-活性-关系研究而得到的一种新型合成化合物，PM742是从石栖目海绵中分离出来的，Theonellidae, Discodermia属(du Bocage 1869)。PM534靶向小管蛋白的整个秋水仙碱结合域，覆盖药效团模型的5个中心中的4个。其纳米摩尔亲和力和高保留时间调节了惊人的高抗肿瘤活性，有效地覆盖了细胞中的两种抗性机制(解毒泵和微管蛋白βIII同型过表达)。此外，PM534对人非小细胞肺癌小鼠异种移植模型的肿瘤生长具有显著的抑制作用。我们的研究结果显示，PM534是一种处于临床前评估阶段的高效新化合物，目前正在进行首次人体I期临床试验。链接网址：https://pubs-acs-org.libproxy1.nus.edu.sg/doi/10.1021/acs.jmedchem.3c01775DOI：https://doi-org.libproxy1.nus.edu.sg/10.1021/acs.jmedchem.3c01775上下滚动查看更多药企动态2023年2月3日【GSK】GSK带状疱疹疫苗新适应症在华申报上市，2023年收入约43亿美元2023年2月2日【创响生物】创响生物获得和黄医药2款自免新药权益2023年2月2日【艾伯维】艾伯维2023年财报：修美乐144亿美元，自免新产品增长强劲2023年2月1日【百吉生物】针对肝癌！百吉生物TIL疗法获FDA快速通道资格2023年2月1日【君实生物】君实生物特瑞普利单抗上市许可申请获新加坡卫生科学局受理2023年1月31日【Teva】仿制药巨头Teva将出售原料药业务2023年1月31日【柯君医药】柯君医药宣布完成亿元B轮融资，加快推进全球临床开发各动态具体信息，请滑动下方文字1.【GSK】2月3日，CDE网站显示，GSK重组带状疱疹疫苗Shingrix新适应症在华申报上市。Shingrix是继Zostavax之后FDA批准的第2款带状疱疹疫苗。该款疫苗最早于2017年10月获FDA批准上市，用于50岁及以上成人带状疱疹的预防；2021年7月，新适应症获FDA批准，用于预防18岁及以上因已知疾病或治疗引起的免疫缺陷或免疫抑制而患带状疱疹风险增加的人群。链接网址请戳我2.【创响生物】2月2日，和黄医药宣布创响生物根据2021年1月11日所宣布的战略合作条款，已行使与和黄医药发现的两款候选药物IMG-007和IMG-004授权许可相关的选择权。行使选择权并于和黄医药收到创响生物约7.5%的普通股股份（完全稀释）后，创响生物将取得在全球进一步开发、生产和商业化上述两款候选药物的独家权益。链接网址请戳我3.【艾伯维】2月2日，艾伯维公布了2023年业绩，全年净收入543.18亿美元，较往年有所下滑（-6.4%）。研发投入为76.75亿美元，同比增长17.9%。艾伯维主要聚焦于5大疾病领域，包括免疫、肿瘤、神经科学、美容以及眼科。其中，免疫学是艾伯维当仁不让的核心业务，共计营收261.36亿美元（-9.6%），占据总收入半壁江山（+48.12%）；其次为神经科学领域，贡献了77.17亿美元收入（+18.2%），这也是艾伯维本年度唯一实现正增长的业务版块；肿瘤、美容、眼科则分别实现了59.15（-10.1%）、52.94（-0.8%）、24.15（-10.6%）亿美元营收。链接网址请戳我4.【百吉生物】2月1日，百吉生物宣布该公司创新TIL疗法BST02注射液被美国FDA授予快速通道资格，用于治疗所有类型的肝癌（包括肝细胞癌和胆管癌）。针对该适应症，BST02已于2023年10月在美国获批临床。链接网址请戳我5.【君实生物】2月1日，君实生物宣布，其自主研发的抗PD-1单抗药物特瑞普利单抗联合顺铂/吉西他滨作为转移性或复发性局部晚期鼻咽癌成人患者的一线治疗，以及作为单药治疗既往含铂治疗过程中或治疗后疾病进展的复发性、不可切除或转移性鼻咽癌的成人患者的2项适应症上市许可申请已于近日获得新加坡卫生科学局（HSA）受理。链接网址请戳我6.【Teva】1月31日，Teva宣布，计划剥离其活性药物成分（API）业务，即TAPI部门。TAPI是全球小分子原料药行业的领导者，拥有约4300名员工。Teva表示，剥离TAPI主要是为了提高当前和未来的业绩收入，重新分配资源以促进增长和创新，更好为患者服务。同时，剥离后的原料药公司也能最大限度地发挥其增长潜力，继续领跑价值850亿美元的全球原料药市场。链接网址请戳我7.【柯君医药】1月31日,创新型药物研发的柯君医药近日宣布顺利完成亿元B轮融资。此轮融资由泰珑投资旗下泰鲲基金领投，其他主要投资方包括骊宸投资、泰煜投资等，原有投资方宏海创健、汉康资本等也持续加持。链接网址请戳我上下滚动查看更多会议信息2024年2月28-29日 举办AntibodyChina 第七届抗体药物深度聚焦峰会2024年3月21-22日 上海恺默信息咨询有限公司举办SIT 2024第六届小分子药物创新与合作大会2024年3月21-22日 上海恺默信息咨询有限公司举办PDD 2024多肽药物产业发展大会2024年4月18-19日 举办第四届I-RNA小核酸药物深度聚焦峰会2024年6月27-28日 举办上海求实医药咨询有限公司ING 2024第七届免疫及基因治疗论坛各会议具体详情和参会方式，请滑动下方文字AntibodyChina 第七届抗体药物深度聚焦峰会会议时间：2024年2月28-29日会议地点：上海会议主旨：峰会议题跨越抗体药物研发的最前沿，追踪最新的临床进展，致力于打破行业的封闭循环，破除行业内卷，助推创新多元发展！一切尽在抗体药物的年度产业大会！链接网址请戳我SIT 2024第六届小分子药物创新与合作大会主办方： 上海恺默信息咨询有限公司会议时间：2024年3月21日-22日会议地点：上海会议主旨：峰会议题跨越小分子药物研发的热点领域，一览当下化学创新药研发新动向，致力于打破行业的封闭循环，破除行业内卷，助推创新多元发展！一切尽在小分子药物的年度产业大会！链接网址请戳我PDD 2024多肽药物产业发展大会主办方： 上海恺默信息咨询有限公司会议时间：2024年3月21日-22日会议地点：上海会议主旨：共谈多肽减重药物、多肽药物的法规与申报、开发案例与趋势、CMC 各个环节中的难点与挑战。力求为多肽企业致力于多肽药物研究的专家及科研人员提供一个深度的思想碰撞及经验分享平台。链接网址请戳我第四届I-RNA小核酸药物深度聚焦峰会会议时间：2024年4月18日-19日会议地点：苏州会议主旨：破解递送挑战与CMC难点，汇聚最新临床进展与热门研发方向；构建小核酸药物专属交流平台，打造产业闭环，推动国产小核酸药物产业化进程。链接网址请戳我ING 2024第七届免疫及基因治疗论坛主办方：上海求实医药咨询有限公司会议时间：2024年6月27日-28日会议地点：北京会议主旨：聚焦CGT领域开发的核心问题，破除技术壁垒，推动产业不断前进，开启生物医药产业下一个风口！链接网址请戳我上下滚动查看更多版权信息本文内容均由小编收集于公开的各个网络平台，发布的目的仅为了方便大家一站式了解AIDD行业信息，并未对发布源头进行真实性验证。如您发现相关信息有任何版权侵扰或者信息错误，请及时联系AIDD Pro（请添加微信号sixiali_fox59）进行删改处理。原创内容未经授权，禁止转载至其他平台。有问题可发邮件至sixiali@stonewise.cn关注我，更多资讯早知道↓↓↓